Rationale and Objective
Current hypertension management guidelines from the European Society of Hypertension/European Society of Cardiology recognise the importance of using combination antihypertensive therapies.1,2 In particular, they recommend that patients with grade 2 (moderate) or 3 (severe) hypertension or with high CV risk receive a two-drug combination as initial treatment.
Combination low dose drug treatment has been shown to increase BP lowering efficacy and reduce CV events, while reducing adverse effects.3
Nifedipine gastrointestinal system (GITS) is a calcium channel-blocker that effectively controls 24-hour blood pressure and was shown to protect hypertensive patients from the occurrence of cardiovascular events in a large randomised trial (INSIGHT).4
Telmisartan is an angiotensin receptor blocker (ARB) known for its superior half-life and 24-hour blood pressure control as compared to other ARBs.5 In the recent ONTARGET trial, telmisartan was shown to prevent CV events in high risk patients both with and without hypertension with a better efficacy:tolerability ratio than the ACE inhibitor ramipril.6
The TALENT study evaluated the best method for co-administration of nifedipine GITS and telmisartan to hypertensive patients with one or more additional CV risk factors.
Combination low dose drug treatment has been shown to increase BP lowering efficacy and reduce CV events, while reducing adverse effects.3
Nifedipine gastrointestinal system (GITS) is a calcium channel-blocker that effectively controls 24-hour blood pressure and was shown to protect hypertensive patients from the occurrence of cardiovascular events in a large randomised trial (INSIGHT).4
Telmisartan is an angiotensin receptor blocker (ARB) known for its superior half-life and 24-hour blood pressure control as compared to other ARBs.5 In the recent ONTARGET trial, telmisartan was shown to prevent CV events in high risk patients both with and without hypertension with a better efficacy:tolerability ratio than the ACE inhibitor ramipril.6
The TALENT study evaluated the best method for co-administration of nifedipine GITS and telmisartan to hypertensive patients with one or more additional CV risk factors.
